LabMed Discovery2026，Vol.3Issue(1)：P.1-9,9.DOI:10.1016/j.lmd.2026.100117
Toward standardized antithrombin activity assays:multi-center evaluation and optimization
Yu Liu 1Ying Song 2Yu-Hua Wang 3Zhen-Ping Chen 4Qiang Li 5Run-Hui Wu 6Jing Sun 7Lei Zhang 3Xiao-Bo Hu 8Ren-Chi Yang 3Xue-Feng Wang 1Jing Dai1
作者信息
- 1. Department of Laboratory Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
- 2. Department of Clinical Hematology and Osteology,Shanghai Center for Clinical Laboratory,Shanghai 200126,China
- 3. State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China
- 4. Department of Clinical Laboratory Center,Beijing Children’s Hospital,Capital Medical University,National Center for Children’s Health,Beijing 100045,China
- 5. Department of Laboratory Medicine,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
- 6. Department of Hematology,Beijing Children’s Hospital,Capital Medical University,National Center for Children’s Health,Beijing 100045,China
- 7. Department of Hematology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
- 8. Shanghai Center for Clinical Laboratory,Shanghai 200126,China
- 折叠
摘要
关键词
Antithrombin(AT)/Standardized testing/Low-level activity measurement/External quality assessment(EQA)分类
医药卫生引用本文复制引用
Yu Liu,Ying Song,Yu-Hua Wang,Zhen-Ping Chen,Qiang Li,Run-Hui Wu,Jing Sun,Lei Zhang,Xiao-Bo Hu,Ren-Chi Yang,Xue-Feng Wang,Jing Dai..Toward standardized antithrombin activity assays:multi-center evaluation and optimization[J].LabMed Discovery,2026,3(1):P.1-9,9.基金项目
supported by the National Natural Science Foundation of China(No.82470131) （No.82470131）
the Research Physician Innovation and Transformation Competence Training Program of Shanghai Shenkang Hospital Development Center,China(No.SHDC2023CRD004). （No.SHDC2023CRD004）
